Burning Rock Biotech logo
Burning Rock Biotech
BNR | NASDAQ
Chart Builder DCF Calculator
$12.74
-$0.55 (-4.14%)
At close: Nov 16, 2026, 4:00 PM ET
$12.74
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

Burning Rock Biotech Company Profile

Company profile explained

Company Profile

Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.

Key Executives

Name Position
Yusheng Han Founder, Chairman & Chief Executive Officer
Zhihong Zhang Chief Technology Officer & Director
Hao Liu Senior Advisor
Xiaozhi Hu Vice President of Finance
Xinru Mao Senior VP of Pharma Biomarker & CDx. Services and International Diagnostics Division

Latest SEC Filings

Date Type Title
Sep 10, 2026 6-K Filing
Jul 02, 2026 4 Filing
Jun 09, 2026 6-K Filing
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Apr 28, 2026 20-F Filing
Apr 02, 2026 4 Filing
Mar 18, 2026 3 Filing
Mar 17, 2026 3 Filing
Mar 17, 2026 3 Filing
View All SEC Filings ➞
Burning Rock Biotech
Burning Rock Biotech logo
Country China
IPO Date Jun 12, 2020
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 667
CEO Yusheng Han

Contact Details

No. 5, Xingdao Ring Road North Guangzhou, GD 510005 China

Stock Details

Ticker Symbol BNR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001792267
CUSIP Number 12233L206
ISIN Number US12233L2060
SIC Code 8071

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.